Log In
Print this Print this

Praluent, alirocumab (REGN727, SAR236553)

Also known as: SAR236553/REGN727

  Manage Alerts
Collapse Summary General Information
Company Sanofi
DescriptionHuman mAb targeting proprotein convertase subtilisin/kexin type 9 (PCSK9)
Molecular Target Proprotein convertase subtilisin/kexin type 9 (PCSK9)
Mechanism of Action 
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentRegistration
Standard IndicationHypercholesterolemia
Indication DetailsTreat autosomal dominant hypercholesterolemia (ADH); Treat heterozygous familial hypercholesterolemia (heFH); Treat hypercholesterolemia; Treat primary hypercholesterolemia
Regulatory Designation

U.S. - Priority Review (Treat hypercholesterolemia);
U.S. - Special Protocol Assessment (Treat hypercholesterolemia);
EU - Standard Review (Treat hypercholesterolemia)


Regeneron Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today